Enoblituzumab, previously known as TJ-271 or MGA271, represents the novel monoclonal targeting CD33, an marker found predominantly on myeloid tissues. Such agent functions as the dual-action molecule, simultaneously https://www.targetmol.com/compound/enoblituzumab